<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35512313</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1948-7193</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS chemical neuroscience</Title>
          <ISOAbbreviation>ACS Chem Neurosci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Purinergic P2X<sub>7</sub> Receptor: A Therapeutic Target in Amyotrophic Lateral Sclerosis.</ArticleTitle>
        <Pagination>
          <StartPage>1479</StartPage>
          <EndPage>1490</EndPage>
          <MedlinePgn>1479-1490</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acschemneuro.2c00133</ELocationID>
        <Abstract>
          <AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by upper and lower motor neuron loss. The pathomechanisms of ALS are still poorly understood with current hypotheses involving genetic mutations, excitotoxicity, and reactive oxygen species formation. In the absence of a disease-altering clinically approved therapeutic, there is an ever-increasing need to identify new targets to develop drugs that delay disease onset and/or progression. The purinergic P2X<sub>7</sub> receptor (P2X<sub>7</sub>R) has been implicated widely across the ALS realm, providing a potential therapeutic strategy. This review summarizes the current understanding of ALS, the P2X<sub>7</sub>R and its role in ALS, the current landscape of P2X<sub>7</sub>R antagonists, and the in vivo potential of these antagonists in preclinical ALS models.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mckenzie</LastName>
            <ForeName>Andr√© D J</ForeName>
            <Initials>ADJ</Initials>
            <Identifier Source="ORCID">0000-0002-8012-4745</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Chemistry, Faculty of Science, University of Sydney, Sydney, New South Wales 2006, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Garrett</LastName>
            <ForeName>Taylor R</ForeName>
            <Initials>TR</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry, Faculty of Science, University of Sydney, Sydney, New South Wales 2006, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Werry</LastName>
            <ForeName>Eryn L</ForeName>
            <Initials>EL</Initials>
            <AffiliationInfo>
              <Affiliation>School of Chemistry, Faculty of Science, University of Sydney, Sydney, New South Wales 2006, Australia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kassiou</LastName>
            <ForeName>Michael</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-6655-0529</Identifier>
            <AffiliationInfo>
              <Affiliation>School of Chemistry, Faculty of Science, University of Sydney, Sydney, New South Wales 2006, Australia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>ACS Chem Neurosci</MedlineTA>
        <NlmUniqueID>101525337</NlmUniqueID>
        <ISSNLinking>1948-7193</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword>
        <Keyword MajorTopicYN="N">P2X7</Keyword>
        <Keyword MajorTopicYN="N">P2X7 receptor antagonists</Keyword>
        <Keyword MajorTopicYN="N">autophagy</Keyword>
        <Keyword MajorTopicYN="N">neuroinflammation</Keyword>
        <Keyword MajorTopicYN="N">purinergic</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>17</Hour>
          <Minute>3</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35512313</ArticleId>
        <ArticleId IdType="doi">10.1021/acschemneuro.2c00133</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
